Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
about
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareNeurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysisDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataSafety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like ChemotherapyIntegrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyPrevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonResource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic RegimensAprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literatureSafety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Effect of Gingerol on Cisplatin-Induced Pica Analogous to Emesis Via Modulating Expressions of Dopamine 2 Receptor, Dopamine Transporter and Tyrosine Hydroxylase in the Vomiting Model of RatsChemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.Safety of neurokinin-1 receptor antagonists.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis.State of the Art Antiemetic Therapy for Cancer Patients.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.The Role of Substance P in Pulmonary Clearance of Bacteria in Comparative Injury Models.Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.EA versus sham acupuncture and no acupuncture for the control of acute and delayed chemotherapy-induced nausea and vomiting: a pilot study.Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.Loss of Neurokinin-1 Receptor Alters Ocular Surface Homeostasis and Promotes an Early Development of Herpes Stromal Keratitis.Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.Are itch and scratching the nausea and vomiting of skin?Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome.Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea.Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.Successful management of refractory diabetic gastroparesis with long-term Aprepitant treatment.A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
P2860
Q26851160-37D50A03-63D1-471D-BF3E-EC6876F62DE3Q26997344-921B1121-7434-4AE3-BBA5-7C64709F7D36Q28084970-F3DA3453-0B52-41D7-9CB2-C8A7E95AF70AQ31061449-0217420C-B9A5-4779-AFE8-4A7C2AF575A8Q33688318-C828994B-E6C4-47A6-99C3-4066928A60BDQ33749075-9F1EC7E8-84BC-4075-B08C-2BEB5091D505Q34166946-DFD49F5E-6E0E-41F7-AAC2-90FC63E5B617Q34437996-6CB0DCFD-FF2F-46EF-A8FC-83F7B4325ABCQ34512212-7B67B0D3-3DC8-44B4-8454-189E2656CA4AQ35248313-D20C4124-EDBF-40F9-AAEA-B5017B29C5A8Q35345557-6B0CA035-9D89-42F0-B9F4-0D6AD80CBC3EQ35970506-41CEE64C-BEE4-4294-9EEB-6B90D6BE0018Q36051908-94036F01-F791-463E-A85C-C4829F2D3618Q36311246-0E33F62D-0EEC-4E87-A0A5-B8E0A0E60F36Q36843470-95C67563-2043-42EC-96A1-E0D263086D88Q37150748-9ADE165B-FC24-4E3C-AC6F-496362F1BCFFQ37174198-E8BAD35B-67C8-49E9-B7C0-B362790EE192Q37593097-D887FA53-F3C6-4BF1-A66C-9FDE6F892149Q37736060-DA29FE0C-BF10-4904-B450-B8EF4981711FQ38109245-D1906F92-B783-4F14-9F25-B3005D860DC5Q38250191-7DAA5C31-339F-491A-9E7E-4EAD5A55C7F6Q38656124-052A8965-D4E6-4591-A673-F357F2B30477Q38676452-33DEF0CC-A3A9-4F1E-9050-9A0C295A94BFQ38677762-92897CE5-3871-41AE-8CBD-57D0DAB3B1B5Q38791941-8C03DD89-D7BB-4560-8D21-E707D1CA02ACQ38792913-F27D3241-BC58-446B-A576-397041D59348Q39001883-A1839D8D-2F52-4AD8-A84D-B0FCC609FFC4Q39213490-6723A279-605D-456F-97D2-2A1095B5CD4EQ39275766-9AEFF11C-FEB8-4314-86F5-AC1A889832BCQ39359365-EC4A99A3-DF16-4978-9C59-DA50FEF53980Q39677350-A9659F63-7CBE-4399-A124-A2DF97C21D08Q40474402-B5EDF9BF-5BAF-4E11-9C83-95227AD5C54CQ40524551-B9C14E87-5B09-4388-B29A-40DAEB21878CQ41103220-F9E6FF4C-4223-4E15-A66F-D44DD90F07F7Q42242954-529B4EAA-B312-46A6-B3D6-8BB7E21973C9Q44470627-3DCB5B4F-8C95-43B8-ACCC-40DC6E77AFCBQ47636194-62D996E3-5D93-4002-B2AA-0D9DD75BCFD5Q48065428-03356175-7DDD-447C-B4BD-533181A703B4Q48243163-58D09865-5ADD-43D1-A9D4-45306F427128Q48302132-93FA2B52-6D99-4FC7-90FD-E6515342A546
P2860
Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neurokinin-1 receptor antagoni ...... vomiting: a systematic review.
@en
type
label
Neurokinin-1 receptor antagoni ...... vomiting: a systematic review.
@en
prefLabel
Neurokinin-1 receptor antagoni ...... vomiting: a systematic review.
@en
P2093
P2860
P356
P1476
Neurokinin-1 receptor antagoni ...... vomiting: a systematic review
@en
P2093
Andre Tesainer Brunetto
Fabiano Hahn Souza
João Paulo da Silveira Nogueira Lima
Lucas Vieira dos Santos
P2860
P304
P356
10.1093/JNCI/DJS335
P407
P577
2012-08-21T00:00:00Z